[COVID-19 impact on the cancer care structuration: Example of the multidisciplinary team meeting dedicated to oncology in Occitanie].

Impact du SARS-CoV2 sur la structuration de la prise en charge du cancer : exemple de la tenue des RCP de cancérologie en Occitanie.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Historique:
received: 07 05 2020
accepted: 14 05 2020
pubmed: 20 5 2020
medline: 29 8 2020
entrez: 20 5 2020
Statut: ppublish

Résumé

This work examines the impact of the SARS-CoV2 epidemic and the organizational recommendations that have been issued since March 16 on tumor boards (TB) activity. The tumor board activity was measured from tumor board sheets extracted from the oncologic electronic file between January 7, 2019 and April 24, 2020. The pre-containment activity was compared to the activity of the containment periods but also to the equivalent periods in 2019. The number of meetings held, the average number of files reviewed per meeting including first presentations and the average number of physicians' attendance were the evaluation criteria. The study covered 191 TB that held 3943 multidisciplinary team meetings (MTM) and reviewed 72,070 files (including 30,127 first submissions). There was a moderate decrease of 8 % in the number of meetings after March 16, 2020. The number of files examined decreased by 23 % in the following month and even more by 33 % in the third period. The physicians' number who attended MTM also decreased by 25 %. The negative impact was higher in the Mediterranean part of the region. This first study of tumor board activity, covering a large region but little affected by the pandemic, shows that its impact on the participation to the MTM has been moderate. In addition, tumor boards have followed the recommendations for optimizing quorum. However, the decrease in average MTM activity, particularly for first submissions, suggests a potential delay in patient management. Complementary qualitative and quantitative works are warranted to estimate the real impact on carcinologic outcomes.

Identifiants

pubmed: 32425210
doi: 10.1016/j.bulcan.2020.05.001
pii: S0007-4551(20)30233-2
pmc: PMC7231733
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

730-737

Informations de copyright

Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Références

Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659

Auteurs

Pascale Grosclaude (P)

Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr.

David Azria (D)

Institut du cancer de Montpellier, fédération universitaire d'oncologie radiothérapie d'Occitanie Méditerranée, département d'oncologie radiothérapie, 298, avenue des Apothicaires, Montpellier cedex 05, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.

Rosine Guimbaud (R)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Oncologie médicale digestive, CHU de Toulouse 31400 Toulouse, France.

Séverine Thibault (S)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.

Laetitia Daubisse-Marliac (L)

Institut Claudius Regaud, IUCT-O, Registre des cancers du Tarn, 31059 Toulouse, France; UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Centre de coordination en cancérologie, CHU de Toulouse, 31000 Toulouse, France.

Guillaume Cartron (G)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Fédération d'Hématologie Universitaire Montpellier-Nïmes, Département d'hématologie clinique, CHU de Montpellier, 34090 Montpellier, France.

Marie-José Renaudie (MJ)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.

Pierre-Adrien Dalbies (PA)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; URPS de médecins libéraux d'Occitanie, 1300, avenue Albert-Einstein, 34000 Montpellier, France.

Jean-Pierre Delord (JP)

Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France; Institut universitaire du cancer de Toulouse, Oncopole, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.

Eric Bauvin (E)

UMR 1027, université de Toulouse Paul Sabatier, Inserm, 31000 Toulouse, France; Réseau régional d'Onco-Occitanie, IUCT-Oncopole, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH